Ultrasound contrast firm Sonus Pharmaceuticals of Bothell, WA, is looking for a new marketing partner in Asia after its licensing deal with Daiichi Pharmaceutical of Japan collapsed. Daiichi and Sonus signed an agreement in 1994, which gave Daiichi
Ultrasound contrast firm Sonus Pharmaceuticals of Bothell, WA, is looking for a new marketing partner in Asia after its licensing deal with Daiichi Pharmaceutical of Japan collapsed. Daiichi and Sonus signed an agreement in 1994, which gave Daiichi rights to Sonus' EchoGen agent in Japan and nine Pacific Rim countries. Daiichi had paid Sonus $12.8 million in option, licensing, and milestone fees as of September 1998.
Daiichi completed phase 1 clinical trials for EchoGen in December 1997 but failed to begin phase 2 studies after that, according to Sonus. Sonus is in the process of looking for a new Asian marketing partner, for both EchoGen and SonoGen (QW7437), the company's next ultrasound contrast agent.
European Society of Breast Imaging Issues Updated Breast Cancer Screening Recommendations
April 24th 2024One of the recommendations from the European Society of Breast Imaging (EUSOBI) is annual breast MRI exams starting at 25 years of age for women deemed to be at high risk for breast cancer.
Study Reveals Benefits of Photon-Counting CT for Assessing Acute Pulmonary Embolism
April 23rd 2024In comparison to energy-integrating detector CT for the workup of suspected acute pulmonary embolism, the use of photon-counting detector CT reduced radiation dosing by 48 percent, according to newly published research.
Could a Newly FDA-Cleared C-Arm Device Bolster Efficiency for Interventional Radiologists?
April 22nd 2024In addition to advanced imaging quality and dose efficiency, the Philips Zenition 30 mobile C-arm device emphasizes personalized user profiles and automated customization to help reduce procedure time.